Beat the Street: Investors eye US inflation; oil; BofA outlook; Eli Lilly
The state of the US economy, where interest rates and inflation are headed keeping investors wary of making big bets.
Significant tech outflows have been reported, shows Bank of America Global Research. Plus, Eli Lily’s diabetes drug gets the UK green light.
US inflation and tech industry concerns
Global investors' cautious approach due to awaiting US inflation data and its impact on interest rates. Concerns about the tech industry's recent decline. Positive news for the pharmaceutical industry with the approval of a diabetes drug from Eli Lilly in the United Kingdom.
Economic uncertainty and market hesitancy
Weak economic data from China contributing to global economic uncertainty. Concerns about prolonged high-interest rates and the challenges faced by the Federal Reserve. Worries about the Chinese economy and potential stimulus measures.
US dollar and Apple's stock
Price Senior market analyst Axel Rudolf discusses the strengthening US dollar, its impact on currencies, and China's restrictions on iPhones affecting Apple's stock price. Tension between China and the US, Apple's product unveiling timing, Bank of America's research on tech stocks, outlook for oil prices, the US dollar, yields, and tighter financial conditions.
Details on outflows from equity funds, tech stocks, and Eli Lilly's diabetes drug approval. Mention of Kroger's earnings and opioid claims against the company. DocuSign's second-quarter results, GameStop's investigation by the US Securities and Exchange Commission, Chevron's liquefied natural gas projects strike in Australia, and potential impacts on gas prices. Updates on oil prices, the US dollar, and gold prices, along with a visual overview of the market before opening.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Start trading forex today
Trade the largest and most volatile financial market in the world.
- Spreads start at just 0.6 points on EUR/USD
- Analyse market movements with our essential selection of charts
- Speculate from a range of platforms, including on mobile
Live prices on most popular markets